Lepu Medical Technology (300003.SZ): MWN105 Injection Completes First Patient Dosing in Phase II Clinical Trial

Stock News09-04

Lepu Medical Technology(Beijing)Co.,Ltd. (300003.SZ) announced that its controlling subsidiary Shanghai Minwei Biotechnology Co., Ltd. ("Minwei Bio") has successfully completed the first patient dosing in a Phase II clinical trial for its independently developed innovative drug MWN105 injection, which is being studied for the treatment of overweight or obesity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1119711674?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-04 16:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119711674","market":"nz","top_or_hot":-1,"title":"Lepu Medical Technology (300003.SZ): MWN105 Injection Completes First Patient Dosing in Phase II Clinical Trial","media":"Stock News","content":"<p>Lepu Medical Technology(Beijing)Co.,Ltd. (300003.SZ) announced that its controlling subsidiary Shanghai Minwei Biotechnology Co., Ltd. (\"Minwei Bio\") has successfully completed the first patient dosing in a Phase II clinical trial for its independently developed innovative drug MWN105 injection, which is being studied for the treatment of overweight or obesity.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lepu Medical Technology (300003.SZ): MWN105 Injection Completes First Patient Dosing in Phase II Clinical Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLepu Medical Technology (300003.SZ): MWN105 Injection Completes First Patient Dosing in Phase II Clinical Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-04 16:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Lepu Medical Technology(Beijing)Co.,Ltd. (300003.SZ) announced that its controlling subsidiary Shanghai Minwei Biotechnology Co., Ltd. (\"Minwei Bio\") has successfully completed the first patient dosing in a Phase II clinical trial for its independently developed innovative drug MWN105 injection, which is being studied for the treatment of overweight or obesity.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0196","symbol_name":"行业龙头","start_time":0,"source_url":"","article_id":"1119711674","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119711674","pubTimestamp":1756973925,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Lepu Medical Technology(Beijing)Co.,Ltd. (300003.SZ) announced that its controlling subsidiary Shanghai Minwei Biotechnology Co., Ltd. (\"Minwei Bio\") has successfully completed the first patient...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300003":"乐普医疗","BK0196":"行业龙头","BK0113":"养老产业","BK0114":"健康中国","BK0201":"可转债","BK0042":"基因检测","BK0251":"专用设备","BK0028":"国家队","BK0188":"融资融券"},"translate_title":"乐普医疗科技（300003.SZ）：MWN105注射液完成II期临床首例患者给药","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300003":1},"content_text":"Lepu Medical Technology(Beijing)Co.,Ltd. (300003.SZ) announced that its controlling subsidiary Shanghai Minwei Biotechnology Co., Ltd. (\"Minwei Bio\") has successfully completed the first patient dosing in a Phase II clinical trial for its independently developed innovative drug MWN105 injection, which is being studied for the treatment of overweight or obesity.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1119711674","isCrawlerRequest":true}